Biodexa tops 50% enrollment in Serenta Phase 3 FAP trial of eRapa

• Biodexa reported recruitment passed the halfway mark in its registrational Phase 3 Serenta trial of eRapa in familial adenomatous polyposis.
• Results have not been presented; the next readout is a planned futility analysis, with a later database lock to support final evaluation.
• The update signals progress toward a pivotal efficacy assessment, a key step toward potential commercialization in a rare gastrointestinal cancer risk condition.
• Enrollment reached 87 of 168 planned subjects, with recruitment running across 29 U.S. and European clinical sites.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608190830PRIMZONEFULLFEED1001258320) on August 19, 2026, and is solely responsible for the information contained therein.